Vitamin K2 sits on solid biology (it activates proteins that help route calcium into bone and away from artery walls), and the human trials are moving in a favorable direction on imaging biomarkers. But the evidence that it prevents fractures or heart events in ordinary, well-nourished people is still thin and inconsistent, so we call it worth-it-for-some rather than a universal buy.
The one-paragraph version
Vitamin K is a cofactor your body uses to "carboxylate" (switch on) a set of proteins, including osteocalcin in bone and matrix Gla protein (MGP) in blood-vessel walls S1S2. K2 (menaquinones, especially MK-7) is the form supplement marketers push for bone and heart interest, contrasting it with K1 (phylloquinone) from leafy greens S1. The mechanism is real and the biomarker data are encouraging — a meta-analysis of 14 RCTs found vitamin K supplementation modestly slowed coronary artery calcification progression and sharply lowered inactive-MGP levels S3. But hard-outcome data (fractures, cardiovascular events) are mixed, and several trials in people who aren't deficient show no benefit on bone density or on some calcification endpoints S2S4. The single most important thing to know is safety-related, not efficacy-related: even small K2 doses can interfere with warfarin S2S6.
What it is and how it works
Vitamin K is a family of fat-soluble compounds that share a function: they act as a coenzyme for the enzyme that carboxylates vitamin-K-dependent (Gla) proteins S1. Three of those proteins matter for this guide:
- Prothrombin and other clotting factors — the classic, undisputed role in normal blood clotting S1.
- Osteocalcin — a bone-matrix protein; carboxylated osteocalcin binds calcium and is associated with bone mineralization S1S2.
- Matrix Gla protein (MGP) — made by vascular smooth-muscle cells; in its active (carboxylated) form it appears to inhibit calcification of soft tissue, including artery walls S1S2.
There are two dietary families. K1 (phylloquinone) is the main form in the Western diet, concentrated in green leafy vegetables and some plant oils; absorption is high from free form but low (roughly 4–17%) from spinach because it's bound in chloroplasts S1. K2 (menaquinones, MK-4 through MK-13) come from bacterial fermentation and some animal foods; natto (fermented soybeans) is exceptionally rich, at roughly 850 mcg per 3 oz S1. Within K2, the two supplemented forms differ: MK-4 clears from blood quickly and has been studied mostly at very high pharmacological doses (45 mg/day in Japanese bone trials), while MK-7 is absorbed well and has a substantially longer half-life, so it raises and sustains blood levels at microgram doses S2S5. That longer half-life is the main reason MK-7 dominates the current supplement market and most recent trials S2S5.
What the evidence actually supports
Biomarkers: consistent. K2 reliably improves the surrogate markers of vitamin K status — it lowers undercarboxylated osteocalcin and lowers dephosphorylated-undercarboxylated MGP (dp-ucMGP), meaning more of these proteins get switched on S2S3. Elevated dp-ucMGP itself is associated with a two- to three-fold higher cardiovascular risk in observational data, which is why it's an attractive target S2.
Vascular calcification: promising but immature. A 2023 systematic review and meta-analysis of 14 RCTs (1,533 participants) found vitamin K supplementation significantly slowed coronary artery calcification progression (mean difference −17.37; 95% CI −34.18 to −0.56) and produced large drops in dp-ucMGP; the authors still concluded K "may have therapeutic potential" and called for more rigorous trials S3. Notably, their meta-regression found no clear difference between K1 and MK-7 forms S3. Against that, a well-run randomized double-blind trial of vitamin K2 (MK-7) plus vitamin D in men with aortic valve calcification did not slow progression of valve calcification versus placebo over two years S4. So the picture is genuinely mixed — favorable in aggregate for coronary artery scores, null in at least one high-quality valve-specific trial S3S4.
Bone: mixed and dose-dependent. Observational Japanese data link higher menaquinone (natto) intake to higher bone mineral density and, in older meta-analysis, high-dose MK-4 (45 mg/day) was associated with fewer hip fractures in postmenopausal women S1S2. But when MK-7 (375 mcg/day) was added on top of calcium and vitamin D for three years, it did not improve bone mineral density despite improving the osteocalcin biomarker S2. A pooled analysis of nine trials suggested lower clinical fracture risk but no consistent gain in bone density or vertebral-fracture outcomes S2. Translation: the biomarker moves, the bone-density needle mostly doesn't in already-replete people S2.
The observational caveat. Much of the enthusiasm traces to population studies (e.g., Rotterdam-type cohorts and Japanese natto cohorts) where higher menaquinone intake tracked with less coronary calcification and lower heart-disease mortality S1S2. Those are correlations and can't establish that K2 itself is responsible S1S2.
Who actually benefits
On current evidence, the strongest rationale is for people with a reason to be vitamin-K under-replete or at high calcification risk — for example, those with chronically elevated dp-ucMGP or conditions like chronic kidney disease that are being studied specifically for this reason S2S3. People who eat very little green-leafy or fermented food may plausibly benefit from correcting low intake S1. For a healthy, well-fed adult with a normal diet, there's no strong outcome evidence that adding K2 changes fracture or cardiovascular risk, and several trials in replete people were null S2S4. This is a "reasonable for some, unproven for most" nutrient, not a universal recommendation.
Dosing (standard, well-established)
These figures describe what guidance and studies use; they are not a recommendation that you personally should take a given amount.
- Adequate Intake (AI) for total vitamin K (there is no RDA): 120 mcg/day for adult men and 90 mcg/day for adult women S1S2. The AI is set for clotting; it's unclear whether it's enough to fully carboxylate bone and vascular proteins S2.
- MK-7 in cardiovascular/bone trials: commonly 90–375 mcg/day, with 180 mcg/day a frequent supplement level S2S3.
- MK-4 in Japanese bone studies: a much larger pharmacological 45 mg/day, reflecting its short half-life — a different regime from microgram MK-7 S2.
- Form and quality: MK-7 is favored in recent research for its longer half-life and steadier blood levels; MK-4 requires far larger, more frequent doses S2S5. Choosing a product verified by an independent quality standard (e.g., USP or third-party testing) is a reasonable generic quality check. K2 is fat-soluble, so it's typically taken with food containing fat S1.
Safety
Vitamin K2 is well tolerated, but two points deserve to be stated plainly, not buried:
- Warfarin interaction — this is the big one. Vitamin K antagonizes warfarin and other vitamin-K-antagonist blood thinners. People on warfarin need consistent vitamin K intake, and even low-dose MK-7 matters: doses as small as 10–20 mcg/day of MK-7 can measurably reduce anticoagulant stability S2S6. If you take warfarin, do not start or change K2 without your clinician and INR monitoring S2S6.
- Toxicity / upper limit. No tolerable upper intake level (UL) has been established for vitamin K, and the Food and Nutrition Board notes no adverse effects reported from food or supplemental K1 or K2 in the general population S1S2. "No known toxicity" is not the same as "study-proven safe at any dose for everyone," and it says nothing about drug interactions S1S2. (Note: the old synthetic form menadione/"K3" is a different, obsolete compound associated with oxidative harm and is not used — this guide is about K1/K2 only S2.)
- Special populations. Pregnancy, and anyone on prescription medications, should check with a clinician first, as this guide's opening note states.
The marketing myths
- "K2 removes calcium from your arteries / reverses calcification." Overstated. The mechanism (activating MGP) is real and biomarkers improve, but the outcome data are mixed — coronary-score progression slowed in a meta-analysis, yet a high-quality aortic-valve trial showed no benefit S3S4. "Slows a surrogate marker in some studies" is not "reverses heart disease."
- "Everyone needs a K2 supplement with their vitamin D." Not established. The D+K2 pairing is biologically plausible, but the aortic-valve RCT that tested exactly that combination was null on its primary endpoint S4. There's no strong evidence a replete person needs it.
- "MK-7 is proven better than MK-4 for outcomes." MK-7 has clearly better pharmacokinetics (longer half-life, effective in micrograms), but meta-analysis found no significant outcome difference between K forms, and head-to-head hard-outcome data are lacking S3S5.
- "It's totally safe for anyone." False for warfarin users — even tiny MK-7 doses can disrupt anticoagulation S2S6.
Every factual claim above is tagged to a numbered source in the frontmatter. This is a draft dossier pending human review; nothing here is medical advice or a directive to take any supplement.
Sources
Every reference below is a primary source cited in this guide.